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Purpose: Arm and lesser saphenous veins (ALSVs) are generally considered to be the best 
alternative for infrapopliteal arterial bypass grafts when greater saphenous vein is not 
available. The need for additional incisions and repositioning of  the patient, along with 
occasional use of  general anesthesia for arm vein harvesting, led to our perception that the 
use of  ALSVs increased operative time and possibly patient discomfort. Therefore, we
compared the outcome of  ALSVs with that of  prosthetic infrapopliteal arterial bypass 
procedures performed at our hospital. 
Methods: Between July 1, 1991, and Dec. 31, 1996, we performed 96 infrapopliteal 
arterial bypass procedures using 45 ALSVs (28 arm vein, 17 lesser saphenous) and 51 
polytetrafluoroethylene (PTFE) grafts. Seventy grafts were single-length ALSV or PTFE 
bypass grafts, and 26 grafts were placed as the distal segment of  a sequential or composite 
bypass graft. Every attempt was made to use ALSV and avoid the use of  PTFE, even if a 
short segment of  the vein graft measured less than 4.0 mm in diameter. There were no 
significant differences between patients with ALSV compared with PTFE grafts in terms 
of  age, sex, indication for surgery, or number of  previous revascularization procedures 
(2.1 vs 1.7), respectively (p > 0.05). However, ALSV grafts had more factors associated 
with an expected worse outcome: they were more commonly anastomosed to pedal 
arteries (17% [8 of  45] vs 0%; p = 0.0009), less commonly single-segment grafts (62% [28 
of 45] vs 82% [42 of 51]; p = 0.03), had higher average runoff resistance values (2.3 vs 
1.5; p = 0.001), and were less frequently treated with lifelong warfarin (65% [29 of 45] 
vs 95% [48 of  51]; p = 0.0001). 
Results: The hospital mortality rate was 3.1% (3 of  96; 3 PTFE). All deaths were 
cardiac-related. Despite the potential factors associated with worse patency rates for 
ALSVs, 2-year assisted primary patency rates tended to be higher for arm veins (46%) 
than for lesser saphenous veins (23%) and PTFE grafts (26%), although this difference was 
not statistically significant. Limb salvage rates were similar between ALSV and PTFE grafts 
(76% vs 71%, respectively). The average operative time was significantly longer for ALSV 
bypass procedures (mean, 6.2 hours) than for PTFE bypass procedures (mean, 4.9 hours; p = 
0.003), and for single-length conduits when revision of previously placed grafts was not 
attempted, the operative time was 4.0 hours for ALSV grafts and 2.5 hours for PTFE grafts. 
Conclusion: In our experience ALSV bypass grafts to infrapopliteal arteries do not 
function as well as reported by some others. In spite of  the extra effort involved, arm vein 
grafts are preferred over PTFE grafts for their likely higher assisted primary patency rates 
and equivalent, if not better, limb salvage rates. (J Vasc Surg 1997;26:919-27.) 
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Greater saphenous vein (GSV) has been shown to 
be the best conduit for infrapopliteal arterial bypass 
grafts) In our experience, this vein is frequently not 
available or usable as a result of  previous peripheral or 
coronary artery bypass procedures, previous vein 
stripping for varicose veins, or inadequate size or 
quality. Prosthetic grafts to infrapopliteal arteries 
yield poor long-term patency rates, although long- 
term anticoagulation thcrapy may improve these re- 
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Table I. Vein graft diameter in 45 ALSV 
infrapopliteal rterial grafts 
Diameur No. of grafts (%) 
3.0 to 3,4 mm 4 (9) 
3.5 to 3.9 mm 10 (22) 
->4.0 mm 31 (69) 
SUits. i'2 Other autologous grafts, namely arm and 
lesser saphenous vein (ALSV), have been reported to 
yield acceptable long-term patency rates by some 
groups2 -8 The use of ALSV involves additional inci- 
sions, possible repositioning of the patient when 
lesser saphenous vein (LSV) is harvested, and use of 
general anesthesia n most patients when long seg- 
ments of arm vein are required. In addition, other 
groups have shown significantly inferior results of 
arm vein grafts compared with GSV grafts. 9 It was 
our perception that harvesting ALSVs was also asso- 
ciated with increased operative time and patient dis- 
comfort. The purpose of this report was to compare 
ALSV and prosthetic grafts for infrapopliteal rterial 
bypass procedures and to determine whether the use 
of ALSV was worth the extra effort to perform these 
challenging operations. 
PATIENTS AND METHODS 
Between July 1, 1991, and December 31, 1996, 
we performed 96 infrapopliteal rterial bypass proce- 
dures in 72 patients using 45 ALSV and 51 pros- 
thetic (polytetrafluoroethylene [PTFE]) grafts at 
Pennsylvania Hospital in Philadelphia. During this 
same period we performed 170 infrapopliteal bypass 
procedures using single-length GSV (not including 
sequential or composite grafts). The indication for 
surgery was limb salvage in all of these cases. 
Veins were routinely mapped before operation 
for all electives cases using duplex ultrasound (DU; 
Advanced Technology Laboratories, Ultramark 
HDI, Bothell, Wash.) for location, quality, and size 
in an accredited vascular laboratory. I f  both GSVs 
were less than 3 mm in diameter based on DU 
assessment or had been previously excised, ALSVs 
were then examined with DU before operation. Arm 
veins were routinely examined after tourniquet appli- 
cation, and LSVs were examined using a tourniquet 
if they were less than 3 mm in diameter when mea- 
sured with the leg in the dependent position. To 
confirm that an apparently small-diameter GSV was 
unusable, during surgery the vein was gently dis- 
tended with heparinized saline solution through a 
side-branch to determine whether it dilated to an 
acceptable diameter (->3.5 mm). If not, the best 
Table II. Comparison of risk factors for 
patients with ALSV (45) vs prosthetic (51) 
Risk factor ALSV PTFE p 
Mean age (yr) 69 
Males 23 
Diabetes mellitus 25 
Chronic renal failure 4 
(dialysis) 
Indication for surgery 





Single-segment conduits 28 
Proximal graft: GSV 5 
Proximal graft: PTFE 8 
Composite arm vein 4 
conduits 
"Pure" vein or PTFE graft* 37 
Distal anastomosis 
Anterior tibial 14 
Peroneal 18 
Posterior tibial 5 
Pedal artery 8 
Adjunctive arteriovenous 0 
fistula 
Lifelong warfarin after 29 
surgery 
Elective 
Runoff resistance value 
(range) 
Operative time (hr) 
(47-91) 72 (45-97) 0.18 
(63%) 29 (57%) 0.53 
(55%) 23 (46%) 0.43 
(7%) 8 (16%) 0.15 
(39%) 27 (52%) 0.20 
(21%) 9 (17%) 0.56 
(40%) 16 (31%) 0.39 
2.1 1.7 0.26 
to 5) (0 to 6) 
(62%) 42 (82%) 0.03 
(11%) 3 (6%) 0.36 
(18%) 6 (12%) 0.40 
(9%) 0 (0%) 0.03 
(82%) 48 (94%) 0.07 
(32%) 15 (29%) 0.72 
(39%) 18 (35%) 0.62 
(11%) 18 (36%) 0.003 
(17%) 0 (0%) 0.0009 
(0%) 22 (43%) <0.0001 
(65%) 48 (95%) 0.0001 
43 (96%) 42 (83%) 0.04 
2.3 1.5 0.001 
(1.0 to 4.0) (1.0 to 4.0) 
6.2 4.9 0.003 
(3.5 to 10) (2 to 8) 
*"Pure," single-segment, composite or sequential grafts of one 
type of conduit: vein (including reater saphenous vein, LSV, or 
arm vein) or PTFE only. 
cctopic vein identified by DU was used. Every at- 
tempt was made to use veins greater than 3.5 mm in 
diameter, measured after arterial inflow was estab- 
lished or after distention with heparinized saline so- 
lution, although if only a short segment was 3.0 to 
3.4 mm in diameter the vein was occasionally used to 
avoid using a prosthetic graft (Table I). If arm vein or 
LSV was not adequate or available (43 cases) or if the 
patient was considered to be at high risk and unable 
to tolerate the additional operativc time to harvest 
these veins (8 cases), a prosthetic graft was used (51 
total cases). Seventy bypass grafts (73%) were single- 
segment grafts, and the other 26 bypass grafts (27%) 
were placed as the distal portion of a sequential or 
composite bypass graft (original proximal graft being 
GSV or PTFE; Table II). 
ALSV bypass grafts included 22 cephalic vein, 17 
lcsser saphcnous vein, four composite arm vcin, and 
two basilic vein grafts. Twenty-nine grafts were re- 
versed because they were equal diameter proximally 
and distally, and 16 were translocated because there 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 6 Calligaro et al. 921 
was a size discrepancy. Translocated vein bypass pro- 
cedures were performed using a 2.8 mm diameter 
angioscope (Olympus, Melville, N.Y.) to ensure 
complete valve lysis. Angioscopy was also liberally 
performed to assess the quality of the lumen of re- 
versed arm veins because of the high incidence of 
luminal defects from previous venipunctures. 1° M- 
though the LSV can be harvested with the patient in 
a supine position through a medial subfascial ap- 
proach or through a separate posterior calf incision, 
we found that exposure of the vein was better with 
the patient in the prone position, s After LSV harvest- 
ing, the patient was turned to a supine position and 
reprepared and draped for the performance of the 
arterial bypass procedure. LSVs were generally re- 
versed for bypass grafts. 
Twenty-two PTFE bypass grafts (43%) had ad- 
junctive distal anastomotic arteriovenous fistulas, 
seven (14%) had vein patches or cuffs at the distal 
anastomosis, and the remaining 22 (43%) were su- 
tured directly to the artery, n-13 Although there was 
no definite standardized approach, adjunctive fistulas 
were generally placed when an adequate-diameter 
tibial vein was present for construction of a fistula 
and when the surgeon believed that a particularly 
poor runoff artery was present. Ringed prosthetic 
grafts were used for all bypass grafts that crossed ajoint. 
Completion intraoperative arteriograms were ob- 
tained for all bypass procedures. More recently, com- 
pletion DU was used for ALSV bypass procedures 
when appropriate quipment and technicians were 
available. 
There were no significant differences between pa- 
tients with ALSV or PTFE grafts in terms of age, sex, 
diabetes mellitus, renal failure, indication for surgery 
(rest pain, ischemic ulcer, gangrene), previous ipsilat- 
eral revascularizations, "pure" conduits composed of 
only vein or only prosthetic, or use of ALSV or PTFE 
as the distal segment of a sequential bypass (Table 
II). However, ALSV grafts were more commonly 
anastomosed to pedal arteries, less frequently main- 
talned on lifelong anticoagulation therapy, less com- 
monly single-segment bypass grafts, and had higher 
average resistance runoff values based on the SVS/ 
ISCVS Ad Hoc Committee on Reporting Standards 
"criteria compared with PTFE grafts (Table II). 14 
Mthough not proved by randomized trials, all four of 
these factors would probably put ALSV grafts at 
more of a disadvantage than PTFE grafts in this 
series. 
Patient information was prospectively entered 
into a computerized registry data base at the time of 
surgery (Microsoft Access). Graft patency for all 
ALSV and prosthetic bypass grafts was assessed using 
clinical evaluation and a graft surveillance protocol, 
which included DU, segmental pressures, and pulse 
volume recordings, performed every 3 months dur- 
ing the first 2 years after surgery and every 6 months 
thereafter. 15,~6 Clinical findings that suggested a fail- 
ing graft were return of preoperative signs and symp- 
toms of arterial insufficiency such as rest pain, a new 
ulcer, or diminished pulses. Decrease in the ankle- 
brachial index more than 0.20 or amplitude o f  ankle 
or transmetatarsal pulse volume recordings more 
than 50% were other criteria that suggested a falling 
graft. Duplex criteria of a failing vein or prosthetic 
graft included peak systolic velocities less than 45 
cm/sec throughout the graft, a peak systolic velocity 
greater than 300 cm/sec at a specific site in the graft 
or anastomosis, or adjacent peak systolic velocity 
ratio greater than 3.0. ~s Patency rates were calcu- 
lated using life table analysis as suggested by the 
SVS/ISCVS Ad Hoc Committee on Reporting Stan- 
dards. 14 Differences in patency rates were calculated 
using the log-rank test. For categoric variables, the 
significance of any differences between groups was 
analyzed by the ×2 test or by Fischer's exact est when 
appropriate. A result was considered statistically sig- 
nificant with a p value less than 0.05, and only pa- 
tency rates with standard errors less than 10% were 
considered statistically relevant. A threatened limb 
was considered successfully salvaged if a major ampu- 
tation was not required, even if a new bypass graft 
other than the original ALSV or PTFE graft proved 
necessary. 
RESULTS 
The hospital mortality rate per bypass procedure 
was 3.1% (three deaths, 96 bypas  grafts, 72 pa- 
tients). Deaths were due to cardiac events and oc- 
curred in patients with PTFE bypass grafts who were 
believed to be at prohibitive risk to undergo ALSV 
harvesting. 
There was no significant difference in 2-year as- 
sisted primary patency rates (32.7% vs 25.6%; p = 
0.82) or secondary patency rates (46.1% vs 54.5%; 
p = 0.17) between ALSV and PTFE grafts, respec- 
tively, based on life-table analysis (Table III). There 
was no significant difference in overall imb salvage 
between the two groups (76% vs 71%; p = 0.59). 
Arm veins tended to have higher assisted 2-year pri- 
mary patency rates than LSV and PTFE grafts (46.0% 
vs 23.5% vs 25.6%), but the difference was not statis- 
tically significant, nor did we find any significant 
differences in 2-year patency rates between PTFE 
grafts with and without adjunctive fistulas or be- 
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Table I I I .  Cumulative 2-year patency rates of  ALSV (45) vs. prosthetic (51) bypasses to 
infrapopliteal arteries 
Total "Pure" grafts Single-segment grafts 
Primary patency 
ALSV 19.0 _+ 6.5% (45) 31.3 _+ 8.9% (37) 27.8 + 9.9% (28) 
Arm vein 29.8 -+ 11.5% (28) 20.0 -+ 10.3% (24) 36.0 -+ 14.4% (18) 
LSV 17.7 +- 9.3% (17) i5.0 -+ 9.8% (13) 10.0 -+ 9.5% (10) 
PTFE 16.7 _+ 6.8% (5I) 21.0 _+ 8.2% (48) 21.0 -+ 8.2% (42) 
Assisted patency 
ALSV 32.7 +_ 7.5% (45) 34.5 _+ 9.0% (37) 33.1 -+ 10.2% (28) 
Arm vein 46.0 -+ 10.8% (28) 45.0 +- 14.9% (24) 55.0 +- 18.4% (18) 
LSV 23.5 +- 10.3% (17) 15.0 +- 9.8% (13) 10.0 -+ 9.5% (10) 
PTFE 25.6 -+ 7.4% (51) 28.4 -+ 7.9% (48) 31.6 -+ 8.7% (42) 
Secondary patency 
ALSV 46.1 _+ 8.1% (45) 44.7 _+ 9.2% (37) 49.1 -+ 10.9% (28) 
Arm vein 55.3 + 10.6% (28) 60.0 -+ 15.5% (24) 64.0 -+ 17.2% (18) 
LSV 34.3 _+ 11.2% (17) 29.0 _+ 14.1% (13) 27.0 + 16.3% (10) 
PTFE 54.5 +_ 8.7% (51) 58.9 +_ 8.5% (48) 6i,8 -+ 8.9% (42) 
Number of grafts in each group at risk in parenthesis. Standard errors greater than 10.0% are not considered statistically relevant. 
"Pure," single-segment, composite or sequential grafts of one type of conduit: vein (including reater saphenous vein, LSV, or arm vein) 
or PTFE only. 
Table IV. Reasons for a failing or failed 
infrapopliteal bypass using ALSV or 
prosthetic graft (96 total) 
Time = 0 to 1 month (17 grafts occluded or revised) 
5 Poor run-off 
4 Technical (2: missed valve, 2: steal through arteriovenous 
fistula) 
4 Small diameter vein 
2 Low cardiac-output 
2 Unknown 
Time < 1 month (54 grafts occluded or revised) 
37 Intimal hyperplasia ( t anastomosis or in vein graft)* 
6 Progression of distal arterial disease 
3 Infection 
1 Small vein 
7 Unlmown 
*Although gross findings ofintimal hyperplasia were identified at 
the site of stenosis when these grafts were directly explored at 
those sites, microscopic studies were not performed to confirm 
this finding. 
tween translocated or reversed ALSV grafts. Reasons 
for a failed or failing graft are listed in Table IV. 
The average operative time was significantly 
longer for ALSV bypass procedures (6.2 hours; 
range, 3.5 to 10 hours) compared with PTFE bypass 
procedures (4.9 hours; range, 2 to 8 hours; p = 
0.003). However,  the average operative time for 
patients who underwent single-length PTFE bypass 
procedures without attempted revision of  previous 
grafts and without placement o f  an adjunctive fistula 
was 2.5 hours, and included the eight patients who 
had PTFE grafts placed because they were consid- 
ered to be at too high a risk to undergo a bypass 
procedure using ALSV. The average operative time 
for patients who underwent single-length arm vein 
bypass procedures without attempted revision of  pre- 
vious grafts was 4.0 hours. An average of  0.5 hours 
was spent for both the completion arteriogram and 
DU when these studies were performed, and these 
tests were included in the operative time. 
The average length o f  hospitalization for patients 
who underwent ALSV bypass procedures was signif- 
icantly shorter (7.5 days; range, 2 to 17 days) com- 
pared with those who undelavent PTFE bypass pro- 
cedures (10.3 days; range, 1 to 29 days; p = 0.04). 
We could not identify reasons for the longer length 
of  hospital stay for patients with PTFE grafts. Three 
patients with prosthetic bypass grafts developed graft 
infections during follow-up; none of  the patients 
with vein bypass grafts did. There were no significant 
complications associated with the 45 ALSVs har- 
vested. Although we did not specifically evaluate 
incisional pain, most patients with a posterior leg 
incision for LSV harvesting mentioned that site as a 
particular annoyance that inhibited early ambulation, 
whereas arm vein incisions were generally well toler- 
ated. 
DISCUSSION 
Revascularization of a chronically ischemic lower 
extremity that requires a bypass graft to an infrapop- 
liteal artery when the GSV has previously been used 
or when it is inadequate is one of  the most challeng- 
ing clinical problems that vascular surgeons face. 
Similar to other tertiary care hospitals that specialize 
in difficult lower extremity revascularizations, more 
than one third o f  infrapopliteal bypass procedures 
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performed at our mcdical center during thc past 5 
years (96 of 266; 36%) were constructed using ALSV 
or PTFE grafts because GSV was not usable. The 
primary patency rates of infrapopliteal rterial bypass 
grafts using these ectopic veins in the current series 
were disappointing compared with a few other cen- 
ters' reports. 3-8 These results occurred despite our 
best efforts to ensure a technically adequate opera- 
Lion, including routine use of preoperative in map- 
ping with DU and intraoperative completion arte- 
riography, and liberal use of angioscopy for arm vein 
conduits, intraoperative completion DU for ALSV 
bypass grafts, adjunctive arteriovenous fistulas and 
vein cuffs or patches for prosthetic bypass grafts, and 
lifelong anticoagulation therapy in the majority of 
patients in both groups. All four vascular surgeons 
who performed these tibial bypass procedures were 
trained at accredited vascular fellowship programs 
that specialized in difficult, redo distal ower extrem- 
ity revascularization procedures. 
Patency rates of'inftapopliteal prosthetic bypass 
grafts in our series compared less favorably with a few 
other series' reports but equally well as some oth- 
ers.l,2,11 3 Flinn et al.2 reported a S-year primary 
patency rate of almost 50% for inftapopliteal pros- 
thetic bypass grafts when patients received chronic 
anticoagulation therapy, whereas the 2-year patency 
rate in the current series was only 17%. However, the 
better patency rates in Flinn's series were achieved 
only in patients who were documented to remain 
adequately anticoagulated using serial blood tests. In 
our series, this was left to the primary care physician. 
More than half of the prosthetic bypass grafts in our 
series had adjunctive arteriovenous fistulas or vein 
cuffs or patches placed at the distal anastomosis, 
which are techniques that have been reported to 
improve prosthetic bypass patency rates. 1>13,17 Ob- 
viously, our results cannot be used to support hese 
claims. The results in our series are more in line with 
the multicenter, prospective randomized trim re- 
ported by Veith et al., ~ which documented primary 
patency rates for prosthetic infrapopliteal bypass 
grafts of only 12% at 4 years. Thereforc, the poor 
patency rates of infrapopliteal tibial bypass grafts in 
the current series are in line with this classic study. 
Although others reported 3- to S-year patency 
rates approximating 40% to 50% for arm vein and 
LSV lower extremity arterial bypass grafts, we ob- 
served a 2-year primary patency rate of only 19%. 38 
Others have also documented inferior results with 
arm vein compared with GSV grafts. 9 Our 2-year 
assisted primary patency rate for single-length arm 
veins (55.0%) was more in line with these other 
published results, but the small numbers of grafts in 
this subgroup probably prevented any statistically 
significant conclusions. We believe our poorer overall 
ALSV results may also be accounted for by several 
significant factors that other reports did not address. 
First, other series of arm and LSV grafts included 
bypass grafts to the popliteal artery in one quarter to 
one third of cases, as opposed to only infrapopliteal 
bypass grafts in our series. 3-8 Second, more than one 
third of the ALSV bypass grafts in our series were the 
distal segment of a sequential or composite graft, 
whereas several other series included only single- 
segment ALSVs. Sequential and composite bypass 
grafts may yield lower patency rates than single- 
segment bypass grafts because of an increased chance 
of graft kinldng or twisting and the need for addi- 
tional anastomoses with a greater likelihood of tech- 
nical error and development of intimal hyperpla- 
sia, 18,19 although aprevious report from our institution 
documented acceptable patcncy rates for sequential 
bypass grafts. 2° Third, we maintained a very aggres- 
sive attitude regarding arterial graft surveillance to 
prevent graft thrombosis and may have intervened 
earlier for some failing grafts than other centers. This 
strategy may have led to our lower primary patency 
rates but ideally should have led to equal or im- 
proved assisted primary patency rates. This is sug- 
gested in the current series but not proven, probably 
because of the small number of certain subsets of 
ALSVs. Fourth, approximately one third of ALSVs in 
our series (14 of 45) mcasured less than 4.0 mm in 
diameter in at least one segment of the graft (Table 
I). This suggests that our poorer results are likely 
related in large part to a difficult case mix. Other 
previously mentioned factors may have had a nega- 
tive impacted, specifically on the patency rates of 
ALSV bypass grafts compared with prosthetic grafts 
in our series, although the effect of these factors on 
patency rates has never clearly been proven. 
The average time required to perform ALSV by- 
pass procedures was significantly longer than the 
time required to perform PTFE bypass procedures, 
although this difference may not be clinically rele- 
vant. The duration of the operation for both ALSV 
and PTFE bypass procedures was extensive because 
of several factors: (1) in most cases an aggressive 
attempt was made to salvage the original graft; (2) 
the majority of patients (76 of 96; 79%) had under- 
gone one or more previous revascularization proce- 
dures, which made reexploration of previously 
scarred tissues difficult and time-consuming; (3) the 
proximal graft of a sequential or composite bypass 
graft was ftequently performed at the same operation 
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as placement of the distal ALSV or PTFE graft to an 
infrapopliteal artery; (4) harvesting ALSVs is proba- 
bly more time-consuming than harvesting GSVs be- 
cause of the increased friability of these ectopic veins 
and relative inaccessibility of the LSV unless the pa- 
tient is repositioned; and (5) approximately half of  
the PTFE grafts had distal anastomotic arteriovenous 
fistulas, which frequently involve friable tibia] veins 
with multiple small branches. This adjunctive tech- 
nique adds a significant length of time to the operation. 
Limbs were salvaged in approximately three quar- 
ters of  these challenging patients after an average 
follow-up of 2 years. However, it should be noted 
that new bypass grafts were frequently required, es- 
pecially in the prosthetic graft group, to achieve limb 
salvage after the ALSV or PTFE graft occluded. 
We found that ALSV and PTFE bypass grafts to 
infrapopliteal arteries yielded low patency rates com- 
pared with a few previously reported results, al- 
though the 2-year assisted primary patency rate of 
55% for single-length arm veins was in line with the 
results in other series. When GSV is not available in 
either leg, we believe that there are several factors 
that favor the construction of arm vein grafts instead 
of PTFE grafts for infrapopliteal bypass procedures. 
Only slightly longer operative times, decreased 
length of hospital stay, possible decreased incidence 
of graft infection, and the trend toward higher as- 
sisted primary patency rates of arm vein grafts, de- 
spite the fact that ALSVs were more commonly anas- 
tomosed to pedal arteries, less likely to be treated 
with anticoagulation mediation, and had higher run- 
off resistance values, make it worth the extra effort to 
use good-quality arm veins as the first choice for 
infrapopliteal bypass grafts instead of using PTFE 
grafts, especially in good-risk patients in whom long- 
term survival is expected. 
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DISCUSSION 
Dr. tL Clement Darl ing I I I  (Albany, N.Y.). Dr. 
Calligaro and his group from Pennsylvania Hospital have 
presented their data on 96 inftapopliteal rterial recon- 
structions in 72 patients using 45 arm and lesser saphenous 
veins and compared them with 51 prosthetic infrapopliteal 
reconstructions. The 2-year primary patency rates were 
24% and 15%, respectively, with an assisted primary pa- 
tency rate of 46% for arm veins, 23% for lesser saphenous 
veins, and 26% for PTFE. The limb salvage rates in these 
patients were 76% and 71%, respectively. Unfortunately, 
the reported patency rates in this series are less than those 
reported in the literature with spliced veins when used for 
secondary and tertiary reconstructions, with a primary pa- 
tency rate of approximately 45%. The difference in the 
results may be a result of certain factors, and I have a few 
questions for Dr. Calligaro. 
First, do you think that the reliance on previous recon- 
structions for inflow, such as you did for composite recon- 
structions, limited the patency rate of these grafts? 
Second, how did you evaluate your inflow? Because 
you were using single segments of vein in many cases, such 
as lesser saphenous vein, which classically only measures 
about 30 cm in length, do you think you used a disadvan- 
taged inflow and outflow and that this could be a reason 
for your decreased patency results? 
Also, you mentioned that early in your experience you 
used a 2.8-mm angioscope liberally, which may have im- 
pacted negatively by causing endothelial trauma. I see that 
you now have changed to using a smaller scope. However, 
that begs the question. When a lesion was recognized in 
the vein as you did your angioscopy, did you perform 
venovenostomies and excise the segment of questionable 
vein or did you accept a compromised segment of that 
venous conduit? In other words, did your angioscopic data 
help you guide your therapy, and did it change any of your 
operations? 
Also, do you think that by harvesting lesser saphenous 
veins prone and then repreparing and draping the patient 
that the prolonged warm ischemia time to this mesenchy- 
real tissue had a negative impact on your results? 
As noted in your paper, we, as well as others, have used 
a single-incision medial approach to the lesser saphenous 
vein to minimize this warm ischemia time, and I was 
wondering whether you could tell whether maybe this 
approach might have helped? 
Also, if you felt that composite grafts did have a nega ~ 
rive impact on your results, do you think it might have 
been better to opt for a new bypass graft primarily and 
avoid the prior operative fields, as this may save operative 
time and avoid any prior disease in the original conduit? 
Lastly, you noted that the average length of hospital- 
ization for the venous reconstruction patients were signifi- 
cantly shorter compared with the PTFE bypass patients. 
Could you elucidate on the reasons for this? 
Dr. Keith D. Calligaro. In answer to the first ques- 
tion, our reliance on previous reconstructions possibly led 
to a lower patency rate. We always obtain preoperative 
arteriograms to document that those inflow grafts were of 
good quality without any stenoses. 
In terms of using single segments of vein, the same 
answer applies. The arteriograms documented that our 
inflow seemed acceptable. 
In terms of the angioscope, we are using a smaller 
scope now, which theoretically causes less intimal damage. 
When a lesion was identified by angioscopy, we would 
aggressively try to repair that lesion. The most common 
lesion to find when you're using arm vein is a fibrotic or 
diseased valve, probably from a previous venipuncture. 
We would cut down on that segment, make a venotomy, 
excise it, and put a vein patch on it, or excise the 
segment and approximate the two ends or place an 
interposition graft. 
The prolonged warm ischemia time is an excellent 
point. When we excise the lesser saphenous vein and then 
reposition the patient, the vein was stored in an iced, 
heparinized saline solution during that time. 
In terms of opting for an entirely new bypass graft 
when we had to splice these smaller segments together, the 
bottom line was that we couldn't opt for a new bypass graft 
unless we were going to use a prosthetic graft. And as I 
said, we've been trying to use any ectopic vein that we 
could. 
The average length of hospitalization was shorter for 
the patients who underwent vein bypass procedures. That 
result may be related to the fact that when you perform a 
tibial bypass procedure with an arm vein, you're only mak- 
ing two small incisions in the leg and then the graft can be 
tunneled subcutaneously. The patients can get up and walk 
the next day or 2 days later, and that may be why they go 
home a little bit earlier. But the other side of the coin is 
that the prosthetic graft patients were probably a little 
sicker in terms of their heart. 
Dr. Ibrahim M. Ibrahim (Englewood, N.J.). As most 
of you know, we use umbilical vein graft when saphenous 
vein is either not usable or not available. On occasion we 
will use an arm vein, but in our experience use of the 
umbilical vein as a conduit has worked equally well when 
compared with cephalic and basilic veins. This has been 
substantiated by others, that is, the patency rate of arm 
veins falls short of that which is attainable with saphenous 
vein, and their patency rates are comparable with ours 
when umbilical vein is used. 
Dr. Calligaro, you used the distal arteriovenous fi tula 
in 40% of the PTFE grafts. How do you decide when and 
when not to use this? Do you notice differential patency 
rates when comparing rafts that have distal arteriovenous 
fistulas with grafts that do not? 
Dr. Calligaro. Thank you, Dr. Ibrahim. We appreciate 
the work that you and Dr. Dardik have done using the 
umbilical vein and the fistulas. 
We tended to use a fistula for some of the smaller 
arteries that had a more disadvantaged outflow, and of 
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course the adjacent tibial vein had to be adequate to use. If  
the tibial veins were too small, then we would not con- 
struct a fistula, obviously. 
Dr. Enrico Ascher (Brooldyn, N.Y.). I want to com- 
mend you on a very honest and clearly presented paper. I
have a couple of questions for you. First, I would like to 
know how you explain such a large difference between your 
limb salvage rates and patcncy rates? That's not what you 
usually see. 
Second, do you have any data, although I know the 
numbers are small, between the patients with PTFE grafts 
with and without fistulas? I might add that this is not really 
only an adjunctive vein we're used to using, but also an 
interposition vein that has a potential advantage of enlarg- 
ing the anastomosis and providing some compliance 
match, although this has not been proven. But I 'm just 
curious to know, because I think you lumped a lot of 
techniques together with few patients, and we may end up 
with the wrong conclusions. 
Dr. Calligaro. The difference in limb salvage and pa- 
tency rates was somewhat surprising. When we analyzed 
the data closer, the difference between the prosthetic graft 
secondary patency rate and the limb salvage rate was about 
15%, which is about what every series has shown. For the 
vein grafts there was a larger difference. Those patients 
needed repeated operations to maintain limb salvage. 
In terms of the fistulas of the prosthetic grafts, about 
half had fistulas. We found a trend favoring the fistulas. But 
again it was not randomized. 
Dr. Robert  W. Hobson  I I  (Newark, N.J.). I enjoyed 
your paper very much. Last year at this Society, as you 
know, we presented some data on the use of a Miller cuff:" 
with mandatory PTFE and reported patency rates at 18 to 
24 months that are about double for femoropopliteal nd 
tibial grafts as you have reported. I am wondering, based 
on your current results, what your posture will be next 
week when you encounter one of these patients and have 
to use a PTFE graft. Is some adjunctive measure necessary? 
If  so, what would your choice be between arteriovenous 
fistula and cuff, either Miller or Taylor? 
Dr. Calligaro. We tried to determine why the results 
were not as good as in some other series. The patients with 
prosthetic grafts all had anticoagulation therapy. Until a 
randomized study is performed, I don't  think we're going 
to have the answer as to whether fistulas, patches, or cuffs are 
better than nothing. 
In answer to your specific question, Dr. Hobson, we 
will either place a fistula or a patch. 
Dr. Marcia A. Gutowicz (Philadelphia, Pa.). One of 
the things you mentioned about the hardest hing, or the 
most problematic circumstance, with using the arm veins is 
that at the valve areas there are very fibrotic areas that have 
to be exciscd and dealt with so as to prevent stricture 
formation. What I found in using arm veins is that they're 
very friable and unforgiving and cause a great deal of injury 
during the harvesting procedure because of the multiple 
tributaries. Historically, there is a paper that describes 
creating a radiocephalic fistula before operation in patients 
so that the vein itself becomes thickened and more durable. 
If  you have time 3 or 4 weeks later, you can harvest he 
cephalic vein and use that for your bypass graft. I was 
wondering whether you ever considered that or had any 
thoughts on that? 
My second question is whether in any cases you used 
the arm veins in a nonreversed, valveless ituation with the 
valvulotome or the valve cutter. Were there any problems 
with additional trauma to these very thin, friable veins 
using the valve cutter or valvulotome? 
Dr. Calligaro. Yes, we are aware of that paper in which 
an arteriovenous fistula was constructed in the arm to 
enlarge and thicken the walls of the arm vein. Although 
that concept is very appealing, there are very few patients 
that we see who can wait a month to 6 weeks for surgery. 
I guess there is an occasional patient with rest pain or a 
very superficial ulcer who could wait for 6 weeks or so to 
undergo the operation, but the vast majority of our 
patients needed revascularization within a week, so I 
don' t  know how many times we could apply that strat- 
egy. 
In answer to your second question, I 'm not quite sure 
I understood it. As I mentioned, almost always the arm 
veins are placed in a translocated fashion where the valves 
were cut with the use of an angioscope. Occasionally, we 
would place them reversed if the wrist diameter was the 
same as in the shoulder, but that was not often. 
Dr. Frank T. Padberg (East Orange, N.J.). A com- 
ment about the warfarin, to further amplify Dr. Hobson's 
comments on our presentation last year regarding vein 
interposition cuffs. We also used warfarin, but not in every 
patient as you have in this series, and found no difference in 
the grafts whether or not the patients had warfarin or not. 
There is a paucity of data regarding the use of warfarin in 
vein grafts, but you'l l  notice that the upcoming program 
at the SVS meeting next month  has a presentation of a 
randomized study conducted by the Veterans Adminis- 
tration in which that question was asked. I wonder 
whether you're still going to continue doing this in the 
future and how you control for the level of  anticoagula- 
tion in these patients. 
Dr. Calligaro. That's an excellent point. We routinely 
give our patients who have a prosthetic infrapopliteal 
bypass heparin at a dose of 500 units per hour in the 
immediate perioperative period. We do that to avoid the 
high incidence of wound hematomas. We're going to 
continue to do this until  there is a randomized study 
that shows that anticoagulation is not any better. We're 
trying to do everything we can to keep those grafts open. 
We then give those patients warfarin beginning the day 
after surgery. 
But the point you're getting at is a very good one. We 
do not manage the warfarin levels. We have our primary 
care physicians or the internists manage our warfarin with 
Strict instructions to keep the international normalized 
ratio at twice the control level. Despite that, very fr¢- 
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quently the international normalized ratio levels become 
subtherapeutic. Whether that really makes a difference, I 'm 
not sure. But the Northwcstcrn study clearly showed that if 
patients are not fully anticoagulated, they had a higher 
incidence of graft thrombosis. 
Dr. Richard M. Green (Rochester, N.Y.). The best 
thing I saw in your slide was that your patients ave in the 
hospital for this long, because, as you know, you are re- 
sponsible for this group going around the country telling 
us how quicldy we have to send our patients home. So can 
we take this home to them and say it's okay to be in the 
hospital 10 days? 
Dr. Galligaro. We still tried to get these patients out 
of the hospital as soon as we could. When you have a 
patient who needs their third or fourth revascularization 
procedure, obviously they're going to be in the hospital 
longer than the first time you perform a femoropopliteal 
abovc-hlee bypass procedure. But yes, Dr. Green, it's fine 
with me to tell your patients that it is okay to be in the 
hospital 10 days. 
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